Advertisement

Index by author

February 01, 2004; Volume 32,Issue 2

A

  1. Achanfuo-Yeboah, Joana

    1. IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF POSACONAZOLE (NOXAFIL)
      Anima Ghosal, Neil Hapangama, Yuan Yuan, Joana Achanfuo-Yeboah, Robert Iannucci, Swapan Chowdhury, Kevin Alton, James E. Patrick and Shmuel Zbaida
      Drug Metabolism and Disposition February 2004, 32 (2) 267-271; DOI: https://doi.org/10.1124/dmd.32.2.267

  2. Alton, Kevin

    1. IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF POSACONAZOLE (NOXAFIL)
      Anima Ghosal, Neil Hapangama, Yuan Yuan, Joana Achanfuo-Yeboah, Robert Iannucci, Swapan Chowdhury, Kevin Alton, James E. Patrick and Shmuel Zbaida
      Drug Metabolism and Disposition February 2004, 32 (2) 267-271; DOI: https://doi.org/10.1124/dmd.32.2.267

  3. Anari, Reza

    1. THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS
      Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
      Drug Metabolism and Disposition February 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246

  4. Ando, Masanori

    1. INVOLVEMENT OF HUMAN HEPATIC UGT1A1, UGT2B4, AND UGT2B7 IN THE GLUCURONIDATION OF CARVEDILOL
      Akiko Ohno, Yoshiro Saito, Nobumitsu Hanioka, Hideto Jinno, Mayumi Saeki, Masanori Ando, Shogo Ozawa and Jun-ichi Sawada
      Drug Metabolism and Disposition February 2004, 32 (2) 235-239; DOI: https://doi.org/10.1124/dmd.32.2.235

  5. Asai, Akira

    1. BIOTRANSFORMATION OF FUCOXANTHINOL INTO AMAROUCIAXANTHIN A IN MICE AND HEPG2 CELLS: FORMATION AND CYTOTOXICITY OF FUCOXANTHIN METABOLITES
      Akira Asai, Tatsuya Sugawara, Hiroshi Ono and Akihiko Nagao
      Drug Metabolism and Disposition February 2004, 32 (2) 205-211; DOI: https://doi.org/10.1124/dmd.32.2.205

  6. Azzarano, Leonard M.

    1. DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY
      Keith W. Ward, Gary J. Stelman, Jayme A. Morgan, Kelli S. Zeigler, Leonard M. Azzarano, Jonathan R. Kehler, Jeanelle E. McSurdy-Freed, Joel W. Proksch and Brian R. Smith
      Drug Metabolism and Disposition February 2004, 32 (2) 172-177; DOI: https://doi.org/10.1124/dmd.32.2.172

B

  1. Baillie, Thomas A.

    1. THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS
      Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
      Drug Metabolism and Disposition February 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246

  2. Beaumont, Kevin

    1. NONLINEAR ORAL PHARMACOKINETICS OF THE α-ANTAGONIST 4-AMINO-5-(4-FLUOROPHENYL)-6,7-DIMETHOXY-2-[4-(MORPHOLINOCARBONYL)-PERHYDRO-1,4-DIAZEPIN-1-YL]QUINOLINE IN HUMANS: USE OF PRECLINICAL DATA TO RATIONALIZE CLINICAL OBSERVATIONS
      Anthony Harrison, Alison Betts, Katherine Fenner, Kevin Beaumont, Alan Edgington, Sarah Roffey, John Davis, Pierre Comby and Paul Morgan
      Drug Metabolism and Disposition February 2004, 32 (2) 197-204; DOI: https://doi.org/10.1124/dmd.32.2.197

  3. Betts, Alison

    1. NONLINEAR ORAL PHARMACOKINETICS OF THE α-ANTAGONIST 4-AMINO-5-(4-FLUOROPHENYL)-6,7-DIMETHOXY-2-[4-(MORPHOLINOCARBONYL)-PERHYDRO-1,4-DIAZEPIN-1-YL]QUINOLINE IN HUMANS: USE OF PRECLINICAL DATA TO RATIONALIZE CLINICAL OBSERVATIONS
      Anthony Harrison, Alison Betts, Katherine Fenner, Kevin Beaumont, Alan Edgington, Sarah Roffey, John Davis, Pierre Comby and Paul Morgan
      Drug Metabolism and Disposition February 2004, 32 (2) 197-204; DOI: https://doi.org/10.1124/dmd.32.2.197

  4. Bonhomme-Faivre, Laurence

    1. EFFECT OF RECOMBINANT INTERLEUKIN-2 PRETREATMENT ON ORAL AND INTRAVENOUS DIGOXIN PHARMACOKINETICS AND P-GLYCOPROTEIN ACTIVITY IN MICE
      Vincent Castagne, Laurence Bonhomme-Faivre, Saik Urien, Makram Ben Reguiga, Mireille Soursac, Francois Gimenez and Robert Farinotti
      Drug Metabolism and Disposition February 2004, 32 (2) 168-171; DOI: https://doi.org/10.1124/dmd.32.2.168

C

  1. Cashman, John R.

    1. EFFECT OF TOTAL PARENTERAL NUTRITION AND CHOLINE ON HEPATIC FLAVIN-CONTAINING AND CYTOCHROME P-450 MONOOXYGENASE ACTIVITY IN RATS
      John R. Cashman, Virginie Lattard and Jing Lin
      Drug Metabolism and Disposition February 2004, 32 (2) 222-229; DOI: https://doi.org/10.1124/dmd.32.2.222

  2. Castagne, Vincent

    1. EFFECT OF RECOMBINANT INTERLEUKIN-2 PRETREATMENT ON ORAL AND INTRAVENOUS DIGOXIN PHARMACOKINETICS AND P-GLYCOPROTEIN ACTIVITY IN MICE
      Vincent Castagne, Laurence Bonhomme-Faivre, Saik Urien, Makram Ben Reguiga, Mireille Soursac, Francois Gimenez and Robert Farinotti
      Drug Metabolism and Disposition February 2004, 32 (2) 168-171; DOI: https://doi.org/10.1124/dmd.32.2.168

  3. Chadwick, Lucas R.

    1. METABOLISM OF 8-PRENYLNARINGENIN, A POTENT PHYTOESTROGEN FROM HOPS (HUMULUS LUPULUS), BY HUMAN LIVER MICROSOMES
      Dejan Nikolic, Yongmei Li, Lucas R. Chadwick, Simonida Grubjesic, Pia Schwab, Peter Metz and Richard B. van Breemen
      Drug Metabolism and Disposition February 2004, 32 (2) 272-279; DOI: https://doi.org/10.1124/dmd.32.2.272

  4. Chiu, Shuet-Hing L.

    1. THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS
      Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
      Drug Metabolism and Disposition February 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246

  5. Chowdhury, Swapan

    1. IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF POSACONAZOLE (NOXAFIL)
      Anima Ghosal, Neil Hapangama, Yuan Yuan, Joana Achanfuo-Yeboah, Robert Iannucci, Swapan Chowdhury, Kevin Alton, James E. Patrick and Shmuel Zbaida
      Drug Metabolism and Disposition February 2004, 32 (2) 267-271; DOI: https://doi.org/10.1124/dmd.32.2.267

  6. Coffee, Richard

    1. DIFFERENTIAL REGULATION OF THE HUMAN CYP3A4 PROMOTER IN TRANSGENIC MICE AND RATS
      Weisheng Zhang, Anthony F. Purchio, Richard Coffee and David B. West
      Drug Metabolism and Disposition February 2004, 32 (2) 163-167; DOI: https://doi.org/10.1124/dmd.32.2.163

  7. Comby, Pierre

    1. NONLINEAR ORAL PHARMACOKINETICS OF THE α-ANTAGONIST 4-AMINO-5-(4-FLUOROPHENYL)-6,7-DIMETHOXY-2-[4-(MORPHOLINOCARBONYL)-PERHYDRO-1,4-DIAZEPIN-1-YL]QUINOLINE IN HUMANS: USE OF PRECLINICAL DATA TO RATIONALIZE CLINICAL OBSERVATIONS
      Anthony Harrison, Alison Betts, Katherine Fenner, Kevin Beaumont, Alan Edgington, Sarah Roffey, John Davis, Pierre Comby and Paul Morgan
      Drug Metabolism and Disposition February 2004, 32 (2) 197-204; DOI: https://doi.org/10.1124/dmd.32.2.197

  8. Cook, Chyung S.

    1. DIFFERENTIAL ENANTIOSELECTIVITY AND PRODUCT-DEPENDENT ACTIVATION AND INHIBITION IN METABOLISM OF VERAPAMIL BY HUMAN CYP3AS
      Lixin Shen, John F. Fitzloff and Chyung S. Cook
      Drug Metabolism and Disposition February 2004, 32 (2) 186-196; DOI: https://doi.org/10.1124/dmd.32.2.186

  9. Cunningham, Paul K.

    1. THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS
      Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
      Drug Metabolism and Disposition February 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246

D

  1. Davis, John

    1. NONLINEAR ORAL PHARMACOKINETICS OF THE α-ANTAGONIST 4-AMINO-5-(4-FLUOROPHENYL)-6,7-DIMETHOXY-2-[4-(MORPHOLINOCARBONYL)-PERHYDRO-1,4-DIAZEPIN-1-YL]QUINOLINE IN HUMANS: USE OF PRECLINICAL DATA TO RATIONALIZE CLINICAL OBSERVATIONS
      Anthony Harrison, Alison Betts, Katherine Fenner, Kevin Beaumont, Alan Edgington, Sarah Roffey, John Davis, Pierre Comby and Paul Morgan
      Drug Metabolism and Disposition February 2004, 32 (2) 197-204; DOI: https://doi.org/10.1124/dmd.32.2.197

  2. Dean, Brian J.

    1. THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS
      Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
      Drug Metabolism and Disposition February 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246

  3. Doss, George A.

    1. IDENTIFICATION OF A HYDROXYLAMINE GLUCURONIDE METABOLITE OF AN ORAL HYPOGLYCEMIC AGENT
      Randall R. Miller, George A. Doss and Ralph A. Stearns
      Drug Metabolism and Disposition February 2004, 32 (2) 178-185; DOI: https://doi.org/10.1124/dmd.32.2.178
    2. THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS
      Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
      Drug Metabolism and Disposition February 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246

E

  1. Edgington, Alan

    1. NONLINEAR ORAL PHARMACOKINETICS OF THE α-ANTAGONIST 4-AMINO-5-(4-FLUOROPHENYL)-6,7-DIMETHOXY-2-[4-(MORPHOLINOCARBONYL)-PERHYDRO-1,4-DIAZEPIN-1-YL]QUINOLINE IN HUMANS: USE OF PRECLINICAL DATA TO RATIONALIZE CLINICAL OBSERVATIONS
      Anthony Harrison, Alison Betts, Katherine Fenner, Kevin Beaumont, Alan Edgington, Sarah Roffey, John Davis, Pierre Comby and Paul Morgan
      Drug Metabolism and Disposition February 2004, 32 (2) 197-204; DOI: https://doi.org/10.1124/dmd.32.2.197

F

  1. Farinotti, Robert

    1. EFFECT OF RECOMBINANT INTERLEUKIN-2 PRETREATMENT ON ORAL AND INTRAVENOUS DIGOXIN PHARMACOKINETICS AND P-GLYCOPROTEIN ACTIVITY IN MICE
      Vincent Castagne, Laurence Bonhomme-Faivre, Saik Urien, Makram Ben Reguiga, Mireille Soursac, Francois Gimenez and Robert Farinotti
      Drug Metabolism and Disposition February 2004, 32 (2) 168-171; DOI: https://doi.org/10.1124/dmd.32.2.168

  2. Feeney, William P.

    1. THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS
      Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
      Drug Metabolism and Disposition February 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246

  3. Fenner, Katherine

    1. NONLINEAR ORAL PHARMACOKINETICS OF THE α-ANTAGONIST 4-AMINO-5-(4-FLUOROPHENYL)-6,7-DIMETHOXY-2-[4-(MORPHOLINOCARBONYL)-PERHYDRO-1,4-DIAZEPIN-1-YL]QUINOLINE IN HUMANS: USE OF PRECLINICAL DATA TO RATIONALIZE CLINICAL OBSERVATIONS
      Anthony Harrison, Alison Betts, Katherine Fenner, Kevin Beaumont, Alan Edgington, Sarah Roffey, John Davis, Pierre Comby and Paul Morgan
      Drug Metabolism and Disposition February 2004, 32 (2) 197-204; DOI: https://doi.org/10.1124/dmd.32.2.197

  4. Finke, Paul E.

    1. THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS
      Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
      Drug Metabolism and Disposition February 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246

  5. Fitzloff, John F.

    1. DIFFERENTIAL ENANTIOSELECTIVITY AND PRODUCT-DEPENDENT ACTIVATION AND INHIBITION IN METABOLISM OF VERAPAMIL BY HUMAN CYP3AS
      Lixin Shen, John F. Fitzloff and Chyung S. Cook
      Drug Metabolism and Disposition February 2004, 32 (2) 186-196; DOI: https://doi.org/10.1124/dmd.32.2.186

  6. Franklin, Ronald B.

    1. THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS
      Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
      Drug Metabolism and Disposition February 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246

  7. Fujii, Toshihiko

    1. POLYMORPHIC EXPRESSION OF CYP1A2 LEADING TO INTERINDIVIDUAL VARIABILITY IN METABOLISM OF A NOVEL BENZODIAZEPINE RECEPTOR PARTIAL INVERSE AGONIST IN DOGS
      Masashi Mise, Seiji Yadera, Michiaki Matsuda, Takanori Hashizume, Satoshi Matsumoto, Yoshiaki Terauchi and Toshihiko Fujii
      Drug Metabolism and Disposition February 2004, 32 (2) 240-245; DOI: https://doi.org/10.1124/dmd.32.2.240

G

  1. Ghosal, Anima

    1. IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF POSACONAZOLE (NOXAFIL)
      Anima Ghosal, Neil Hapangama, Yuan Yuan, Joana Achanfuo-Yeboah, Robert Iannucci, Swapan Chowdhury, Kevin Alton, James E. Patrick and Shmuel Zbaida
      Drug Metabolism and Disposition February 2004, 32 (2) 267-271; DOI: https://doi.org/10.1124/dmd.32.2.267

  2. Gimenez, Francois

    1. EFFECT OF RECOMBINANT INTERLEUKIN-2 PRETREATMENT ON ORAL AND INTRAVENOUS DIGOXIN PHARMACOKINETICS AND P-GLYCOPROTEIN ACTIVITY IN MICE
      Vincent Castagne, Laurence Bonhomme-Faivre, Saik Urien, Makram Ben Reguiga, Mireille Soursac, Francois Gimenez and Robert Farinotti
      Drug Metabolism and Disposition February 2004, 32 (2) 168-171; DOI: https://doi.org/10.1124/dmd.32.2.168

  3. Grubjesic, Simonida

    1. METABOLISM OF 8-PRENYLNARINGENIN, A POTENT PHYTOESTROGEN FROM HOPS (HUMULUS LUPULUS), BY HUMAN LIVER MICROSOMES
      Dejan Nikolic, Yongmei Li, Lucas R. Chadwick, Simonida Grubjesic, Pia Schwab, Peter Metz and Richard B. van Breemen
      Drug Metabolism and Disposition February 2004, 32 (2) 272-279; DOI: https://doi.org/10.1124/dmd.32.2.272

H

  1. Hall, Stephen D.

    1. PREDICTION OF CYTOCHROME P450 3A INHIBITION BY VERAPAMIL ENANTIOMERS AND THEIR METABOLITES
      Ying-Hong Wang, David R. Jones and Stephen D. Hall
      Drug Metabolism and Disposition February 2004, 32 (2) 259-266; DOI: https://doi.org/10.1124/dmd.32.2.259

  2. Hanioka, Nobumitsu

    1. INVOLVEMENT OF HUMAN HEPATIC UGT1A1, UGT2B4, AND UGT2B7 IN THE GLUCURONIDATION OF CARVEDILOL
      Akiko Ohno, Yoshiro Saito, Nobumitsu Hanioka, Hideto Jinno, Mayumi Saeki, Masanori Ando, Shogo Ozawa and Jun-ichi Sawada
      Drug Metabolism and Disposition February 2004, 32 (2) 235-239; DOI: https://doi.org/10.1124/dmd.32.2.235

  3. Hapangama, Neil

    1. IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF POSACONAZOLE (NOXAFIL)
      Anima Ghosal, Neil Hapangama, Yuan Yuan, Joana Achanfuo-Yeboah, Robert Iannucci, Swapan Chowdhury, Kevin Alton, James E. Patrick and Shmuel Zbaida
      Drug Metabolism and Disposition February 2004, 32 (2) 267-271; DOI: https://doi.org/10.1124/dmd.32.2.267

  4. Harrison, Anthony

    1. NONLINEAR ORAL PHARMACOKINETICS OF THE α-ANTAGONIST 4-AMINO-5-(4-FLUOROPHENYL)-6,7-DIMETHOXY-2-[4-(MORPHOLINOCARBONYL)-PERHYDRO-1,4-DIAZEPIN-1-YL]QUINOLINE IN HUMANS: USE OF PRECLINICAL DATA TO RATIONALIZE CLINICAL OBSERVATIONS
      Anthony Harrison, Alison Betts, Katherine Fenner, Kevin Beaumont, Alan Edgington, Sarah Roffey, John Davis, Pierre Comby and Paul Morgan
      Drug Metabolism and Disposition February 2004, 32 (2) 197-204; DOI: https://doi.org/10.1124/dmd.32.2.197

  5. Hashizume, Takanori

    1. POLYMORPHIC EXPRESSION OF CYP1A2 LEADING TO INTERINDIVIDUAL VARIABILITY IN METABOLISM OF A NOVEL BENZODIAZEPINE RECEPTOR PARTIAL INVERSE AGONIST IN DOGS
      Masashi Mise, Seiji Yadera, Michiaki Matsuda, Takanori Hashizume, Satoshi Matsumoto, Yoshiaki Terauchi and Toshihiko Fujii
      Drug Metabolism and Disposition February 2004, 32 (2) 240-245; DOI: https://doi.org/10.1124/dmd.32.2.240

  6. Hop, Cornelis E.C.A.

    1. THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS
      Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
      Drug Metabolism and Disposition February 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246

  7. Huskey, Su-Er W.

    1. THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS
      Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
      Drug Metabolism and Disposition February 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246

I

  1. Iannucci, Robert

    1. IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF POSACONAZOLE (NOXAFIL)
      Anima Ghosal, Neil Hapangama, Yuan Yuan, Joana Achanfuo-Yeboah, Robert Iannucci, Swapan Chowdhury, Kevin Alton, James E. Patrick and Shmuel Zbaida
      Drug Metabolism and Disposition February 2004, 32 (2) 267-271; DOI: https://doi.org/10.1124/dmd.32.2.267

J

  1. Jinno, Hideto

    1. INVOLVEMENT OF HUMAN HEPATIC UGT1A1, UGT2B4, AND UGT2B7 IN THE GLUCURONIDATION OF CARVEDILOL
      Akiko Ohno, Yoshiro Saito, Nobumitsu Hanioka, Hideto Jinno, Mayumi Saeki, Masanori Ando, Shogo Ozawa and Jun-ichi Sawada
      Drug Metabolism and Disposition February 2004, 32 (2) 235-239; DOI: https://doi.org/10.1124/dmd.32.2.235

  2. Jones, David R.

    1. PREDICTION OF CYTOCHROME P450 3A INHIBITION BY VERAPAMIL ENANTIOMERS AND THEIR METABOLITES
      Ying-Hong Wang, David R. Jones and Stephen D. Hall
      Drug Metabolism and Disposition February 2004, 32 (2) 259-266; DOI: https://doi.org/10.1124/dmd.32.2.259

K

  1. Kato, Takako

    1. AN EVALUATION METHOD FOR NONLINEAR LOCAL DISPOSITION IN RAT LIVER AND KIDNEY
      Takako Kato, Kiyoshi Yamaoka and Yoshinobu Takakura
      Drug Metabolism and Disposition February 2004, 32 (2) 230-234; DOI: https://doi.org/10.1124/dmd.32.2.230

  2. Kehler, Jonathan R.

    1. DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY
      Keith W. Ward, Gary J. Stelman, Jayme A. Morgan, Kelli S. Zeigler, Leonard M. Azzarano, Jonathan R. Kehler, Jeanelle E. McSurdy-Freed, Joel W. Proksch and Brian R. Smith
      Drug Metabolism and Disposition February 2004, 32 (2) 172-177; DOI: https://doi.org/10.1124/dmd.32.2.172

  3. Kim, John

    1. STEREOSELECTIVE PHARMACOKINETICS OF FLUOXETINE AND NORFLUOXETINE ENANTIOMERS IN PREGNANT SHEEP
      John Kim, K. Wayne Riggs and Dan W. Rurak
      Drug Metabolism and Disposition February 2004, 32 (2) 212-221; DOI: https://doi.org/10.1124/dmd.32.2.212

L

  1. Lattard, Virginie

    1. EFFECT OF TOTAL PARENTERAL NUTRITION AND CHOLINE ON HEPATIC FLAVIN-CONTAINING AND CYTOCHROME P-450 MONOOXYGENASE ACTIVITY IN RATS
      John R. Cashman, Virginie Lattard and Jing Lin
      Drug Metabolism and Disposition February 2004, 32 (2) 222-229; DOI: https://doi.org/10.1124/dmd.32.2.222

  2. Li, Yongmei

    1. METABOLISM OF 8-PRENYLNARINGENIN, A POTENT PHYTOESTROGEN FROM HOPS (HUMULUS LUPULUS), BY HUMAN LIVER MICROSOMES
      Dejan Nikolic, Yongmei Li, Lucas R. Chadwick, Simonida Grubjesic, Pia Schwab, Peter Metz and Richard B. van Breemen
      Drug Metabolism and Disposition February 2004, 32 (2) 272-279; DOI: https://doi.org/10.1124/dmd.32.2.272

  3. Lin, Jing

    1. EFFECT OF TOTAL PARENTERAL NUTRITION AND CHOLINE ON HEPATIC FLAVIN-CONTAINING AND CYTOCHROME P-450 MONOOXYGENASE ACTIVITY IN RATS
      John R. Cashman, Virginie Lattard and Jing Lin
      Drug Metabolism and Disposition February 2004, 32 (2) 222-229; DOI: https://doi.org/10.1124/dmd.32.2.222

M

  1. Matsuda, Michiaki

    1. POLYMORPHIC EXPRESSION OF CYP1A2 LEADING TO INTERINDIVIDUAL VARIABILITY IN METABOLISM OF A NOVEL BENZODIAZEPINE RECEPTOR PARTIAL INVERSE AGONIST IN DOGS
      Masashi Mise, Seiji Yadera, Michiaki Matsuda, Takanori Hashizume, Satoshi Matsumoto, Yoshiaki Terauchi and Toshihiko Fujii
      Drug Metabolism and Disposition February 2004, 32 (2) 240-245; DOI: https://doi.org/10.1124/dmd.32.2.240

  2. Matsumoto, Satoshi

    1. POLYMORPHIC EXPRESSION OF CYP1A2 LEADING TO INTERINDIVIDUAL VARIABILITY IN METABOLISM OF A NOVEL BENZODIAZEPINE RECEPTOR PARTIAL INVERSE AGONIST IN DOGS
      Masashi Mise, Seiji Yadera, Michiaki Matsuda, Takanori Hashizume, Satoshi Matsumoto, Yoshiaki Terauchi and Toshihiko Fujii
      Drug Metabolism and Disposition February 2004, 32 (2) 240-245; DOI: https://doi.org/10.1124/dmd.32.2.240

  3. McSurdy-Freed, Jeanelle E.

    1. DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY
      Keith W. Ward, Gary J. Stelman, Jayme A. Morgan, Kelli S. Zeigler, Leonard M. Azzarano, Jonathan R. Kehler, Jeanelle E. McSurdy-Freed, Joel W. Proksch and Brian R. Smith
      Drug Metabolism and Disposition February 2004, 32 (2) 172-177; DOI: https://doi.org/10.1124/dmd.32.2.172

  4. Metz, Peter

    1. METABOLISM OF 8-PRENYLNARINGENIN, A POTENT PHYTOESTROGEN FROM HOPS (HUMULUS LUPULUS), BY HUMAN LIVER MICROSOMES
      Dejan Nikolic, Yongmei Li, Lucas R. Chadwick, Simonida Grubjesic, Pia Schwab, Peter Metz and Richard B. van Breemen
      Drug Metabolism and Disposition February 2004, 32 (2) 272-279; DOI: https://doi.org/10.1124/dmd.32.2.272

  5. Miller, Randall R.

    1. IDENTIFICATION OF A HYDROXYLAMINE GLUCURONIDE METABOLITE OF AN ORAL HYPOGLYCEMIC AGENT
      Randall R. Miller, George A. Doss and Ralph A. Stearns
      Drug Metabolism and Disposition February 2004, 32 (2) 178-185; DOI: https://doi.org/10.1124/dmd.32.2.178

  6. Mise, Masashi

    1. POLYMORPHIC EXPRESSION OF CYP1A2 LEADING TO INTERINDIVIDUAL VARIABILITY IN METABOLISM OF A NOVEL BENZODIAZEPINE RECEPTOR PARTIAL INVERSE AGONIST IN DOGS
      Masashi Mise, Seiji Yadera, Michiaki Matsuda, Takanori Hashizume, Satoshi Matsumoto, Yoshiaki Terauchi and Toshihiko Fujii
      Drug Metabolism and Disposition February 2004, 32 (2) 240-245; DOI: https://doi.org/10.1124/dmd.32.2.240

  7. Morgan, Jayme A.

    1. DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY
      Keith W. Ward, Gary J. Stelman, Jayme A. Morgan, Kelli S. Zeigler, Leonard M. Azzarano, Jonathan R. Kehler, Jeanelle E. McSurdy-Freed, Joel W. Proksch and Brian R. Smith
      Drug Metabolism and Disposition February 2004, 32 (2) 172-177; DOI: https://doi.org/10.1124/dmd.32.2.172

  8. Morgan, Paul

    1. NONLINEAR ORAL PHARMACOKINETICS OF THE α-ANTAGONIST 4-AMINO-5-(4-FLUOROPHENYL)-6,7-DIMETHOXY-2-[4-(MORPHOLINOCARBONYL)-PERHYDRO-1,4-DIAZEPIN-1-YL]QUINOLINE IN HUMANS: USE OF PRECLINICAL DATA TO RATIONALIZE CLINICAL OBSERVATIONS
      Anthony Harrison, Alison Betts, Katherine Fenner, Kevin Beaumont, Alan Edgington, Sarah Roffey, John Davis, Pierre Comby and Paul Morgan
      Drug Metabolism and Disposition February 2004, 32 (2) 197-204; DOI: https://doi.org/10.1124/dmd.32.2.197

N

  1. Nagao, Akihiko

    1. BIOTRANSFORMATION OF FUCOXANTHINOL INTO AMAROUCIAXANTHIN A IN MICE AND HEPG2 CELLS: FORMATION AND CYTOTOXICITY OF FUCOXANTHIN METABOLITES
      Akira Asai, Tatsuya Sugawara, Hiroshi Ono and Akihiko Nagao
      Drug Metabolism and Disposition February 2004, 32 (2) 205-211; DOI: https://doi.org/10.1124/dmd.32.2.205

  2. Nikolic, Dejan

    1. METABOLISM OF 8-PRENYLNARINGENIN, A POTENT PHYTOESTROGEN FROM HOPS (HUMULUS LUPULUS), BY HUMAN LIVER MICROSOMES
      Dejan Nikolic, Yongmei Li, Lucas R. Chadwick, Simonida Grubjesic, Pia Schwab, Peter Metz and Richard B. van Breemen
      Drug Metabolism and Disposition February 2004, 32 (2) 272-279; DOI: https://doi.org/10.1124/dmd.32.2.272

O

  1. Ohno, Akiko

    1. INVOLVEMENT OF HUMAN HEPATIC UGT1A1, UGT2B4, AND UGT2B7 IN THE GLUCURONIDATION OF CARVEDILOL
      Akiko Ohno, Yoshiro Saito, Nobumitsu Hanioka, Hideto Jinno, Mayumi Saeki, Masanori Ando, Shogo Ozawa and Jun-ichi Sawada
      Drug Metabolism and Disposition February 2004, 32 (2) 235-239; DOI: https://doi.org/10.1124/dmd.32.2.235

  2. Ono, Hiroshi

    1. BIOTRANSFORMATION OF FUCOXANTHINOL INTO AMAROUCIAXANTHIN A IN MICE AND HEPG2 CELLS: FORMATION AND CYTOTOXICITY OF FUCOXANTHIN METABOLITES
      Akira Asai, Tatsuya Sugawara, Hiroshi Ono and Akihiko Nagao
      Drug Metabolism and Disposition February 2004, 32 (2) 205-211; DOI: https://doi.org/10.1124/dmd.32.2.205

  3. Ozawa, Shogo

    1. INVOLVEMENT OF HUMAN HEPATIC UGT1A1, UGT2B4, AND UGT2B7 IN THE GLUCURONIDATION OF CARVEDILOL
      Akiko Ohno, Yoshiro Saito, Nobumitsu Hanioka, Hideto Jinno, Mayumi Saeki, Masanori Ando, Shogo Ozawa and Jun-ichi Sawada
      Drug Metabolism and Disposition February 2004, 32 (2) 235-239; DOI: https://doi.org/10.1124/dmd.32.2.235

P

  1. Patrick, James E.

    1. IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF POSACONAZOLE (NOXAFIL)
      Anima Ghosal, Neil Hapangama, Yuan Yuan, Joana Achanfuo-Yeboah, Robert Iannucci, Swapan Chowdhury, Kevin Alton, James E. Patrick and Shmuel Zbaida
      Drug Metabolism and Disposition February 2004, 32 (2) 267-271; DOI: https://doi.org/10.1124/dmd.32.2.267

  2. Proksch, Joel W.

    1. DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY
      Keith W. Ward, Gary J. Stelman, Jayme A. Morgan, Kelli S. Zeigler, Leonard M. Azzarano, Jonathan R. Kehler, Jeanelle E. McSurdy-Freed, Joel W. Proksch and Brian R. Smith
      Drug Metabolism and Disposition February 2004, 32 (2) 172-177; DOI: https://doi.org/10.1124/dmd.32.2.172

  3. Purchio, Anthony F.

    1. DIFFERENTIAL REGULATION OF THE HUMAN CYP3A4 PROMOTER IN TRANSGENIC MICE AND RATS
      Weisheng Zhang, Anthony F. Purchio, Richard Coffee and David B. West
      Drug Metabolism and Disposition February 2004, 32 (2) 163-167; DOI: https://doi.org/10.1124/dmd.32.2.163

R

  1. Reguiga, Makram Ben

    1. EFFECT OF RECOMBINANT INTERLEUKIN-2 PRETREATMENT ON ORAL AND INTRAVENOUS DIGOXIN PHARMACOKINETICS AND P-GLYCOPROTEIN ACTIVITY IN MICE
      Vincent Castagne, Laurence Bonhomme-Faivre, Saik Urien, Makram Ben Reguiga, Mireille Soursac, Francois Gimenez and Robert Farinotti
      Drug Metabolism and Disposition February 2004, 32 (2) 168-171; DOI: https://doi.org/10.1124/dmd.32.2.168

  2. Riggs, K. Wayne

    1. STEREOSELECTIVE PHARMACOKINETICS OF FLUOXETINE AND NORFLUOXETINE ENANTIOMERS IN PREGNANT SHEEP
      John Kim, K. Wayne Riggs and Dan W. Rurak
      Drug Metabolism and Disposition February 2004, 32 (2) 212-221; DOI: https://doi.org/10.1124/dmd.32.2.212

  3. Robichaud, Albert J.

    1. THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS
      Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
      Drug Metabolism and Disposition February 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246

  4. Roffey, Sarah

    1. NONLINEAR ORAL PHARMACOKINETICS OF THE α-ANTAGONIST 4-AMINO-5-(4-FLUOROPHENYL)-6,7-DIMETHOXY-2-[4-(MORPHOLINOCARBONYL)-PERHYDRO-1,4-DIAZEPIN-1-YL]QUINOLINE IN HUMANS: USE OF PRECLINICAL DATA TO RATIONALIZE CLINICAL OBSERVATIONS
      Anthony Harrison, Alison Betts, Katherine Fenner, Kevin Beaumont, Alan Edgington, Sarah Roffey, John Davis, Pierre Comby and Paul Morgan
      Drug Metabolism and Disposition February 2004, 32 (2) 197-204; DOI: https://doi.org/10.1124/dmd.32.2.197

  5. Rurak, Dan W.

    1. STEREOSELECTIVE PHARMACOKINETICS OF FLUOXETINE AND NORFLUOXETINE ENANTIOMERS IN PREGNANT SHEEP
      John Kim, K. Wayne Riggs and Dan W. Rurak
      Drug Metabolism and Disposition February 2004, 32 (2) 212-221; DOI: https://doi.org/10.1124/dmd.32.2.212

S

  1. Saeki, Mayumi

    1. INVOLVEMENT OF HUMAN HEPATIC UGT1A1, UGT2B4, AND UGT2B7 IN THE GLUCURONIDATION OF CARVEDILOL
      Akiko Ohno, Yoshiro Saito, Nobumitsu Hanioka, Hideto Jinno, Mayumi Saeki, Masanori Ando, Shogo Ozawa and Jun-ichi Sawada
      Drug Metabolism and Disposition February 2004, 32 (2) 235-239; DOI: https://doi.org/10.1124/dmd.32.2.235

  2. Saito, Yoshiro

    1. INVOLVEMENT OF HUMAN HEPATIC UGT1A1, UGT2B4, AND UGT2B7 IN THE GLUCURONIDATION OF CARVEDILOL
      Akiko Ohno, Yoshiro Saito, Nobumitsu Hanioka, Hideto Jinno, Mayumi Saeki, Masanori Ando, Shogo Ozawa and Jun-ichi Sawada
      Drug Metabolism and Disposition February 2004, 32 (2) 235-239; DOI: https://doi.org/10.1124/dmd.32.2.235

  3. Sawada, Jun-ichi

    1. INVOLVEMENT OF HUMAN HEPATIC UGT1A1, UGT2B4, AND UGT2B7 IN THE GLUCURONIDATION OF CARVEDILOL
      Akiko Ohno, Yoshiro Saito, Nobumitsu Hanioka, Hideto Jinno, Mayumi Saeki, Masanori Ando, Shogo Ozawa and Jun-ichi Sawada
      Drug Metabolism and Disposition February 2004, 32 (2) 235-239; DOI: https://doi.org/10.1124/dmd.32.2.235

  4. Schwab, Pia

    1. METABOLISM OF 8-PRENYLNARINGENIN, A POTENT PHYTOESTROGEN FROM HOPS (HUMULUS LUPULUS), BY HUMAN LIVER MICROSOMES
      Dejan Nikolic, Yongmei Li, Lucas R. Chadwick, Simonida Grubjesic, Pia Schwab, Peter Metz and Richard B. van Breemen
      Drug Metabolism and Disposition February 2004, 32 (2) 272-279; DOI: https://doi.org/10.1124/dmd.32.2.272

  5. Shen, Lixin

    1. DIFFERENTIAL ENANTIOSELECTIVITY AND PRODUCT-DEPENDENT ACTIVATION AND INHIBITION IN METABOLISM OF VERAPAMIL BY HUMAN CYP3AS
      Lixin Shen, John F. Fitzloff and Chyung S. Cook
      Drug Metabolism and Disposition February 2004, 32 (2) 186-196; DOI: https://doi.org/10.1124/dmd.32.2.186

  6. Smith, Brian R.

    1. DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY
      Keith W. Ward, Gary J. Stelman, Jayme A. Morgan, Kelli S. Zeigler, Leonard M. Azzarano, Jonathan R. Kehler, Jeanelle E. McSurdy-Freed, Joel W. Proksch and Brian R. Smith
      Drug Metabolism and Disposition February 2004, 32 (2) 172-177; DOI: https://doi.org/10.1124/dmd.32.2.172

  7. Soursac, Mireille

    1. EFFECT OF RECOMBINANT INTERLEUKIN-2 PRETREATMENT ON ORAL AND INTRAVENOUS DIGOXIN PHARMACOKINETICS AND P-GLYCOPROTEIN ACTIVITY IN MICE
      Vincent Castagne, Laurence Bonhomme-Faivre, Saik Urien, Makram Ben Reguiga, Mireille Soursac, Francois Gimenez and Robert Farinotti
      Drug Metabolism and Disposition February 2004, 32 (2) 168-171; DOI: https://doi.org/10.1124/dmd.32.2.168

  8. Stearns, Ralph A.

    1. IDENTIFICATION OF A HYDROXYLAMINE GLUCURONIDE METABOLITE OF AN ORAL HYPOGLYCEMIC AGENT
      Randall R. Miller, George A. Doss and Ralph A. Stearns
      Drug Metabolism and Disposition February 2004, 32 (2) 178-185; DOI: https://doi.org/10.1124/dmd.32.2.178

  9. Stelman, Gary J.

    1. DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY
      Keith W. Ward, Gary J. Stelman, Jayme A. Morgan, Kelli S. Zeigler, Leonard M. Azzarano, Jonathan R. Kehler, Jeanelle E. McSurdy-Freed, Joel W. Proksch and Brian R. Smith
      Drug Metabolism and Disposition February 2004, 32 (2) 172-177; DOI: https://doi.org/10.1124/dmd.32.2.172

  10. Strauss, John R.

    1. THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS
      Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
      Drug Metabolism and Disposition February 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246

  11. Sugawara, Tatsuya

    1. BIOTRANSFORMATION OF FUCOXANTHINOL INTO AMAROUCIAXANTHIN A IN MICE AND HEPG2 CELLS: FORMATION AND CYTOTOXICITY OF FUCOXANTHIN METABOLITES
      Akira Asai, Tatsuya Sugawara, Hiroshi Ono and Akihiko Nagao
      Drug Metabolism and Disposition February 2004, 32 (2) 205-211; DOI: https://doi.org/10.1124/dmd.32.2.205

T

  1. Takakura, Yoshinobu

    1. AN EVALUATION METHOD FOR NONLINEAR LOCAL DISPOSITION IN RAT LIVER AND KIDNEY
      Takako Kato, Kiyoshi Yamaoka and Yoshinobu Takakura
      Drug Metabolism and Disposition February 2004, 32 (2) 230-234; DOI: https://doi.org/10.1124/dmd.32.2.230

  2. Terauchi, Yoshiaki

    1. POLYMORPHIC EXPRESSION OF CYP1A2 LEADING TO INTERINDIVIDUAL VARIABILITY IN METABOLISM OF A NOVEL BENZODIAZEPINE RECEPTOR PARTIAL INVERSE AGONIST IN DOGS
      Masashi Mise, Seiji Yadera, Michiaki Matsuda, Takanori Hashizume, Satoshi Matsumoto, Yoshiaki Terauchi and Toshihiko Fujii
      Drug Metabolism and Disposition February 2004, 32 (2) 240-245; DOI: https://doi.org/10.1124/dmd.32.2.240

U

  1. Urien, Saik

    1. EFFECT OF RECOMBINANT INTERLEUKIN-2 PRETREATMENT ON ORAL AND INTRAVENOUS DIGOXIN PHARMACOKINETICS AND P-GLYCOPROTEIN ACTIVITY IN MICE
      Vincent Castagne, Laurence Bonhomme-Faivre, Saik Urien, Makram Ben Reguiga, Mireille Soursac, Francois Gimenez and Robert Farinotti
      Drug Metabolism and Disposition February 2004, 32 (2) 168-171; DOI: https://doi.org/10.1124/dmd.32.2.168

V

  1. van Breemen, Richard B.

    1. METABOLISM OF 8-PRENYLNARINGENIN, A POTENT PHYTOESTROGEN FROM HOPS (HUMULUS LUPULUS), BY HUMAN LIVER MICROSOMES
      Dejan Nikolic, Yongmei Li, Lucas R. Chadwick, Simonida Grubjesic, Pia Schwab, Peter Metz and Richard B. van Breemen
      Drug Metabolism and Disposition February 2004, 32 (2) 272-279; DOI: https://doi.org/10.1124/dmd.32.2.272

W

  1. Wang, Bonnie

    1. THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS
      Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
      Drug Metabolism and Disposition February 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246

  2. Wang, Ying-Hong

    1. PREDICTION OF CYTOCHROME P450 3A INHIBITION BY VERAPAMIL ENANTIOMERS AND THEIR METABOLITES
      Ying-Hong Wang, David R. Jones and Stephen D. Hall
      Drug Metabolism and Disposition February 2004, 32 (2) 259-266; DOI: https://doi.org/10.1124/dmd.32.2.259

  3. Wang, Zhen

    1. THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS
      Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
      Drug Metabolism and Disposition February 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246

  4. Ward, Keith W.

    1. DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY
      Keith W. Ward, Gary J. Stelman, Jayme A. Morgan, Kelli S. Zeigler, Leonard M. Azzarano, Jonathan R. Kehler, Jeanelle E. McSurdy-Freed, Joel W. Proksch and Brian R. Smith
      Drug Metabolism and Disposition February 2004, 32 (2) 172-177; DOI: https://doi.org/10.1124/dmd.32.2.172

  5. West, David B.

    1. DIFFERENTIAL REGULATION OF THE HUMAN CYP3A4 PROMOTER IN TRANSGENIC MICE AND RATS
      Weisheng Zhang, Anthony F. Purchio, Richard Coffee and David B. West
      Drug Metabolism and Disposition February 2004, 32 (2) 163-167; DOI: https://doi.org/10.1124/dmd.32.2.163

Y

  1. Yadera, Seiji

    1. POLYMORPHIC EXPRESSION OF CYP1A2 LEADING TO INTERINDIVIDUAL VARIABILITY IN METABOLISM OF A NOVEL BENZODIAZEPINE RECEPTOR PARTIAL INVERSE AGONIST IN DOGS
      Masashi Mise, Seiji Yadera, Michiaki Matsuda, Takanori Hashizume, Satoshi Matsumoto, Yoshiaki Terauchi and Toshihiko Fujii
      Drug Metabolism and Disposition February 2004, 32 (2) 240-245; DOI: https://doi.org/10.1124/dmd.32.2.240

  2. Yamaoka, Kiyoshi

    1. AN EVALUATION METHOD FOR NONLINEAR LOCAL DISPOSITION IN RAT LIVER AND KIDNEY
      Takako Kato, Kiyoshi Yamaoka and Yoshinobu Takakura
      Drug Metabolism and Disposition February 2004, 32 (2) 230-234; DOI: https://doi.org/10.1124/dmd.32.2.230

  3. Yuan, Yuan

    1. IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF POSACONAZOLE (NOXAFIL)
      Anima Ghosal, Neil Hapangama, Yuan Yuan, Joana Achanfuo-Yeboah, Robert Iannucci, Swapan Chowdhury, Kevin Alton, James E. Patrick and Shmuel Zbaida
      Drug Metabolism and Disposition February 2004, 32 (2) 267-271; DOI: https://doi.org/10.1124/dmd.32.2.267

Z

  1. Zbaida, Shmuel

    1. IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF POSACONAZOLE (NOXAFIL)
      Anima Ghosal, Neil Hapangama, Yuan Yuan, Joana Achanfuo-Yeboah, Robert Iannucci, Swapan Chowdhury, Kevin Alton, James E. Patrick and Shmuel Zbaida
      Drug Metabolism and Disposition February 2004, 32 (2) 267-271; DOI: https://doi.org/10.1124/dmd.32.2.267

  2. Zeigler, Kelli S.

    1. DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY
      Keith W. Ward, Gary J. Stelman, Jayme A. Morgan, Kelli S. Zeigler, Leonard M. Azzarano, Jonathan R. Kehler, Jeanelle E. McSurdy-Freed, Joel W. Proksch and Brian R. Smith
      Drug Metabolism and Disposition February 2004, 32 (2) 172-177; DOI: https://doi.org/10.1124/dmd.32.2.172

  3. Zhang, Minghua

    1. THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS
      Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
      Drug Metabolism and Disposition February 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246

  4. Zhang, Weisheng

    1. DIFFERENTIAL REGULATION OF THE HUMAN CYP3A4 PROMOTER IN TRANSGENIC MICE AND RATS
      Weisheng Zhang, Anthony F. Purchio, Richard Coffee and David B. West
      Drug Metabolism and Disposition February 2004, 32 (2) 163-167; DOI: https://doi.org/10.1124/dmd.32.2.163
Back to top

In this issue